Nick Mireles is a writer on the central coast of California. He has a knack for film, music, and Dungeons and Dragons. When he’s not writing, he tries to spend his days reading, surfing, and camping ...

The convergence of CNS and oncology research amplifies the significance of Oncotelic’s recent intellectual property updates for OT-101. Developed in collaboration with Sapu Bioscience, the expanded ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today ...

Arbor will also present data demonstrating continued progress of its CNS programs, including the demonstration of in vivo proof-of-concept data supporting the first type V gene editing program for ...

In 1996, the AACN published a consensus statement on the essentials of master's education in nursing that identified a common educational core. [2] This core consists of 3 layers: (1) a graduate core ...

Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE ...

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a ...

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and ...

Results presented at the American Society of Gene and Cell Therapy 25th Annual Meeting CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy ...

The MarketWatch News Department was not involved in the creation of this content. Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell ...

– Presentations demonstrate progress in advancing portfolio of CNS gene editing programs in SOD1 ALS and first data presented on company’s Angelman syndrome program – Data showcase specificity ...